Quality of Life and Self-esteem After Botox® Injections in Depressed and Non-depressed Patients
Primary Purpose
Depression, Quality of Life
Status
Completed
Phase
Phase 4
Locations
Brazil
Study Type
Interventional
Intervention
Botulinum Toxin Type A
Sponsored by

About this trial
This is an interventional treatment trial for Depression focused on measuring Depression, Botulinum toxin, Glabella, Quality of life, Self-steem
Eligibility Criteria
Inclusion Criteria:
- Female subjects,aged between 25 to 60 years;
- Subjects diagnosed as having major depression according to the criteria of DSM-IV, MINI International Neuropsychiatric Interview (MINI Brazilian version 5.0.0);
- Subjects who are being administered a therapeutic dose of an approved, prescribed antidepressant medication (pattern doses of the literature), and have been using mentioned medication at a stable therapeutic dose for at least three months prior to the randomization visit;
- Subjects with mild (1), moderate (2) or severe (3) glabellar frown lines while at rest according the Severity Wrinkles Scales;
- Female subjects of childbearing age that present a negative urine pregnancy test and are using an effective contraceptive method;
- Subjects who had never received botulinum toxin A previously;
- Subjects agreeing to take part of the study, after being fully informed of the purpose and the nature of the investigation and after having signed the informed consent form;
- Subjects who will be available throughout the duration of the study;
- Subjects with sufficient schooling and awareness to enable them to cooperate to the degree required by this protocol;
- Subjects with Critical appreciation preserved, attested by their assistant psychiatrist (for group1);
- Subjects who reside with other family members who assume co-responsibility in the study.
Exclusion Criteria:
- Subjects whose medical history and physical examination present clinical pathology, as myasthenia gravis, Eaton-Lambert Syndrome, neoplasm, muscular diseases, motor neuron diseases, systemic autoimmune or neurological diseases;
- Pregnant or women in breastfeeding, or women planning to become pregnant
- Subjects with suicide risk;
- Subjects addicted to alcohol or illegal drugs within the last 6 months;
- Subjects using amino glycoside and penicillamine antibiotics, quinine and Ca2+ channel blockers;
- Subjects using medications that, in the opinion of the investigator may cause depression, such as beta-blockers, oral corticosteroids and interferon;
- Subjects who, in the opinion of the investigator, may potentially require psychiatric hospitalization during the course of the study;
- Subjects with inflammation or active infection in the area to be injected;
- Subjects with a history of non-adherence to medical treatment, or who demonstrate unwillingness to adhere to the study protocol;
- The presence of any additional active DSM-IV Axis I diagnosis, or mental retardation;
- History of psychiatric hospitalization within the past three years.
Sites / Locations
- Brazilian Center for Studies in Dermatology
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Depressed subjects
Non Depressed subjects
Arm Description
Diagnosis of depression (diagnostic criteria from DSM-IV-TR and MINI International Neuropsychiatric Interview - Brazilian version 5.0.)They must be using a therapeutic dose of antidepressant for at least 2 months before the intervention prescribed by a psychiatrist.
Subjects with no diagnosis of depression
Outcomes
Primary Outcome Measures
Rosenberg Self-Esteem Scale
Measure of self esteem for research purposes.
Ten questions graded from 0 to 3 as described below:
Questions 1, 3, 4, 7, 10
0 - Totally agree
- Agree
- Disagree
- Totally disagree
Questions 2, 5, 6, 8, 9
3 - Totally agree 2 - Agree
1 - Disagree 0 - Totally disagree
The scale ranges from 0-30. Scores between 15 and 25 are within normal range; scores below 15 suggest low self-esteem.
Beck Depression Inventory (BDI)
BDI is a 21-question multiple-choice self-report inventory, one of the most widely used psychometric tests for measuring the severity of depression. Each question is graded from 0 to 3.
0-9: indicates minimal depression 10-18: indicates mild depression 19-29: indicates moderate depression 30-63: indicates severe depression.
Secondary Outcome Measures
WHOQOL-BREF
The WHOQOL-BREF is a scale for the quality of life assessment developed by the World Health Organization. It is composed by 26 questions graded from 1 to 5.
Scoring:
1 to 2.9 - needs improvement 3 to 3.9 - regular 4 to 4.9 - good 5 - very good
Question 1 asks about the individual's overall perception of quality of life. Results refer to question 1.
Wrinkle Severity Scale (WSS) at Rest
The injection of botulinum toxin type A causes muscle paralysis, reducing facial lines. Wrinkle scales are used to grade the muscular effects of botulinum toxin.
The WSS is a 4-point validated scale for forehead lines:
0 - None
- Mild
- Moderate
- Severe
Wrinkle Severity Scale (WSS) at Maximum Contraction
The injection of botulinum toxin type A causes muscle paralysis, reducing facial lines. Wrinkle scales are used to grade the muscular effects of botulinum toxin.
The WSS is a 4-point validated scale for forehead lines:
0 - None
- Mild
- Moderate
- Severe
Full Information
NCT ID
NCT01004042
First Posted
October 28, 2009
Last Updated
January 7, 2021
Sponsor
Brazilan Center for Studies in Dermatology
Collaborators
Allergan
1. Study Identification
Unique Protocol Identification Number
NCT01004042
Brief Title
Quality of Life and Self-esteem After Botox® Injections in Depressed and Non-depressed Patients
Official Title
Evaluation of Quality of Life and Self-esteem After Botulinum Toxin type-a (Botox®) Injections in Depressed and Non-depressed Patients
Study Type
Interventional
2. Study Status
Record Verification Date
January 2021
Overall Recruitment Status
Completed
Study Start Date
October 2009 (undefined)
Primary Completion Date
March 2010 (Actual)
Study Completion Date
April 2010 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Brazilan Center for Studies in Dermatology
Collaborators
Allergan
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The primary objective of this study is to determine the alterations in quality of life and self-esteem after BOTOX® injections in the glabella in depressed and non-depressed patients.
The secondary objective of this study are:
to assess wrinkles improvement
to evaluate depressive symptoms using Beck Depression Inventory before and after Botox® injections.
to elucidate that depression is not a contraindication for botulinum toxin injections.
Detailed Description
The study consists of two groups: one with diagnosis of depression (diagnostic criteria from DSM-IV-TR and MINI International Neuropsychiatric Interview - Brazilian version 5.0) and other without diagnosis of depression.
Subjects with depression will be part of group 1. They must be using a therapeutic dose of antidepressant for at least 2 months before the intervention prescribed by a psychiatrist.
Subjects with no diagnosis of depression will be part of group 2. Subjects included in the study will receive injections of 20 U (as minimal dose) to 40 U (as maximum dose) of BTX-A (BOTOX®, Allergan, USA) diluted in 0.9% saline, according to standard injections of 4U in 5 points of glabellar area as the treatment.
Four visits will be scheduled. Visit 0 (baseline), Visit 1 (intervention), visit 2 (4 weeks), visit 3 (8 weeks) visit 4 (12 weeks).
The scales for the assessment of depressive symptoms, Beck Depression Inventory (BDI), will be applied at visits 1,2,3,4; WHOQOL BREF will be applied at baseline visit and 4.
Rosenberg Self-Esteem Scale will be applied in all visits. Photographs will be taken as well as the dermatological evaluation of the wrinkles and folds will be assessed using a 4-points validated Severity Wrinkles Scale, and psychiatric evaluation as well, in both groups.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Depression, Quality of Life
Keywords
Depression, Botulinum toxin, Glabella, Quality of life, Self-steem
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
50 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Depressed subjects
Arm Type
Active Comparator
Arm Description
Diagnosis of depression (diagnostic criteria from DSM-IV-TR and MINI International Neuropsychiatric Interview - Brazilian version 5.0.)They must be using a therapeutic dose of antidepressant for at least 2 months before the intervention prescribed by a psychiatrist.
Arm Title
Non Depressed subjects
Arm Type
Active Comparator
Arm Description
Subjects with no diagnosis of depression
Intervention Type
Drug
Intervention Name(s)
Botulinum Toxin Type A
Other Intervention Name(s)
Botox®
Intervention Description
Subjects included in the study will receive injections of 20 U (as minimal dose) to 40 U (as maximum dose) of BTX-A (BOTOX®/Allergan, USA) diluted in 0.9% saline, according to standard injections of 4U in 5 points of glabellar area as the treatment.
Primary Outcome Measure Information:
Title
Rosenberg Self-Esteem Scale
Description
Measure of self esteem for research purposes.
Ten questions graded from 0 to 3 as described below:
Questions 1, 3, 4, 7, 10
0 - Totally agree
- Agree
- Disagree
- Totally disagree
Questions 2, 5, 6, 8, 9
3 - Totally agree 2 - Agree
1 - Disagree 0 - Totally disagree
The scale ranges from 0-30. Scores between 15 and 25 are within normal range; scores below 15 suggest low self-esteem.
Time Frame
Baseline, Day 1 (intervention), Week 4, Week 8, Week 12
Title
Beck Depression Inventory (BDI)
Description
BDI is a 21-question multiple-choice self-report inventory, one of the most widely used psychometric tests for measuring the severity of depression. Each question is graded from 0 to 3.
0-9: indicates minimal depression 10-18: indicates mild depression 19-29: indicates moderate depression 30-63: indicates severe depression.
Time Frame
Baseline, Day 1 (intervention), Week 4, Week 8, Week 12
Secondary Outcome Measure Information:
Title
WHOQOL-BREF
Description
The WHOQOL-BREF is a scale for the quality of life assessment developed by the World Health Organization. It is composed by 26 questions graded from 1 to 5.
Scoring:
1 to 2.9 - needs improvement 3 to 3.9 - regular 4 to 4.9 - good 5 - very good
Question 1 asks about the individual's overall perception of quality of life. Results refer to question 1.
Time Frame
Baseline, Day 1 (intervention), Week 4, Week 8, Week 12
Title
Wrinkle Severity Scale (WSS) at Rest
Description
The injection of botulinum toxin type A causes muscle paralysis, reducing facial lines. Wrinkle scales are used to grade the muscular effects of botulinum toxin.
The WSS is a 4-point validated scale for forehead lines:
0 - None
- Mild
- Moderate
- Severe
Time Frame
Baseline, Week 4, Week 8, Week 12
Title
Wrinkle Severity Scale (WSS) at Maximum Contraction
Description
The injection of botulinum toxin type A causes muscle paralysis, reducing facial lines. Wrinkle scales are used to grade the muscular effects of botulinum toxin.
The WSS is a 4-point validated scale for forehead lines:
0 - None
- Mild
- Moderate
- Severe
Time Frame
Baseline, Day 1 (intervention), Week 4, Week 8, Week 12
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
25 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Female subjects,aged between 25 to 60 years;
Subjects diagnosed as having major depression according to the criteria of DSM-IV, MINI International Neuropsychiatric Interview (MINI Brazilian version 5.0.0);
Subjects who are being administered a therapeutic dose of an approved, prescribed antidepressant medication (pattern doses of the literature), and have been using mentioned medication at a stable therapeutic dose for at least three months prior to the randomization visit;
Subjects with mild (1), moderate (2) or severe (3) glabellar frown lines while at rest according the Severity Wrinkles Scales;
Female subjects of childbearing age that present a negative urine pregnancy test and are using an effective contraceptive method;
Subjects who had never received botulinum toxin A previously;
Subjects agreeing to take part of the study, after being fully informed of the purpose and the nature of the investigation and after having signed the informed consent form;
Subjects who will be available throughout the duration of the study;
Subjects with sufficient schooling and awareness to enable them to cooperate to the degree required by this protocol;
Subjects with Critical appreciation preserved, attested by their assistant psychiatrist (for group1);
Subjects who reside with other family members who assume co-responsibility in the study.
Exclusion Criteria:
Subjects whose medical history and physical examination present clinical pathology, as myasthenia gravis, Eaton-Lambert Syndrome, neoplasm, muscular diseases, motor neuron diseases, systemic autoimmune or neurological diseases;
Pregnant or women in breastfeeding, or women planning to become pregnant
Subjects with suicide risk;
Subjects addicted to alcohol or illegal drugs within the last 6 months;
Subjects using amino glycoside and penicillamine antibiotics, quinine and Ca2+ channel blockers;
Subjects using medications that, in the opinion of the investigator may cause depression, such as beta-blockers, oral corticosteroids and interferon;
Subjects who, in the opinion of the investigator, may potentially require psychiatric hospitalization during the course of the study;
Subjects with inflammation or active infection in the area to be injected;
Subjects with a history of non-adherence to medical treatment, or who demonstrate unwillingness to adhere to the study protocol;
The presence of any additional active DSM-IV Axis I diagnosis, or mental retardation;
History of psychiatric hospitalization within the past three years.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Doris M Hexsel, MD
Organizational Affiliation
Brazilian Center For Studies in Dermatology
Official's Role
Principal Investigator
Facility Information:
Facility Name
Brazilian Center for Studies in Dermatology
City
Porto Alegre
State/Province
Rio Grande Do Sul
ZIP/Postal Code
90570 040
Country
Brazil
12. IPD Sharing Statement
Learn more about this trial
Quality of Life and Self-esteem After Botox® Injections in Depressed and Non-depressed Patients
We'll reach out to this number within 24 hrs